Tumor invasion and oxidative stress: Biomarkers and therapeutic strategies

Current Molecular Medicine

Volumn 12, Issue 6, 2012, Pages 746-762

  Muinelo Romay, L ^a   Alonso Alconada, L ^a   Alonso Nocelo, M ^a   Barbazan, J ^a   Abal, M ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Anti cancer therapy; Biomarker; Carcinoma invasion; Hypoxia; Inflammation; Metastasis; Oxidative stress; Ros

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALDEHYDE OXIDASE; ANTHRACYCLINE DERIVATIVE; APOPTOSIS SIGNAL REGULATING KINASE 1; ARSENIC TRIOXIDE; BIOLOGICAL MARKER; BLEOMYCIN; CISPLATIN; COLLAGENASE 3; CURCUMIN; GELATINASE B; GLUTATHIONE PEROXIDASE 3; GLYCOGEN SYNTHASE KINASE 3BETA; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERSTITIAL COLLAGENASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROCARBAZINE; RESVERATROL; STRESS ACTIVATED PROTEIN KINASE; STROMELYSIN 2; SUPEROXIDE DISMUTASE; THIOREDOXIN REDUCTASE 1; TRANSCRIPTION FACTOR ETS 1; TRANSCRIPTION FACTOR NRF2; TRANSCRIPTION FACTOR SNAIL; UNINDEXED DRUG; VIMENTIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR STRESS RESPONSE; DNA DAMAGE; DRUG CYTOTOXICITY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; GENOMIC INSTABILITY; HODGKIN DISEASE; HUMAN; LEUKEMIA; LIPID PEROXIDATION; METASTASIS; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MUTAGENESIS; NONHODGKIN LYMPHOMA; OXIDATION; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PHOTODYNAMIC THERAPY; PHOTOOXIDATION; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASMS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84862538931     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652412800792570     Document Type: Article

References (193)

1. Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 2011; 17: 320-9.
2. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392-401.
3. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006; 66: 605-12.
4. Pani G, Galeotti T, Chiarugi P. Metastasis: cancer cell's escape from oxidative stress. Cancer Metastasis Rev 2010; 29: 351-78.
5. Haviv I, Polyak K, Qiu W, Hu M, Campbell I. Origin of carcinoma associated fibroblasts. Cell Cycle 2009; 8: 589-95.
6. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-74.
7. Redon CE, Dickey JS, Nakamura AJ, et al. Tumors induce complex DNA damage in distant proliferative tissues in vivo. Proc Natl Acad Sci USA 107: 17992-7.
8. Kryston TB, Georgiev AB, Pissis P, Georgakilas AG. Role of oxidative stress and DNA damage in human carcinogenesis. Mutat Res 711: 193-201.
9. Martin OA, Redon CE, Nakamura AJ, et al. Systemic DNA damage related to cancer. Cancer Res 2011; 71: 3437-41.
10. Rajendran R, Garva R, Krstic-Demonacos M, Demonacos C. Sirtuins: molecular traffic lights in the crossroad of oxidative stress, chromatin remodeling, and transcription. J Biomed Biotechnol 2011: 368276.
11. Lindsay J, Jiao X, Sakamaki T, et al. ErbB2 induces Notch1 activity and function in breast cancer cells. Clin Transl Sci 2008; 1: 107-15.
12. Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer- Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NFkappaB- Dependent Manner. Cancer Cell 2010; 17: 135-47.
13. Hayward SW, Wang Y, Cao M, et al. Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res 2001; 61: 8135-42.
14. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121: 335-48.
15. Wen DS, Zhu XL, Guan SM, et al. Silencing of CXCR4 inhibits the proliferation, adhesion, chemotaxis and invasion of salivary gland mucoepidermoid carcinoma Mc3 cells in vitro. Oral Oncol 2008; 44: 545-54.
16. Yang F, Tuxhorn JA, Ressler SJ, et al. Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res 2005; 65: 8887-95.
17. Nelson CM, Bissell MJ. Modeling dynamic reciprocity: engineering three-dimensional culture models of breast architecture, function, and neoplastic transformation. Semin Cancer Biol 2005; 15: 342-52.
18. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387-92.
19. Holliday DL, Hughes S, Shaw JA, Walker RA, Jones JL. Intrinsic genetic characteristics determine tumor-modifying capacity of fibroblasts: matrix metalloproteinase-3 5A/5A genotype enhances breast cancer cell invasion. Breast Cancer Res 2007; 9: R67.
20. Durackova Z. Some current insights into oxidative stress. Physiol Res 2010; 59: 459-69.
21. Jabs T. Reactive oxygen intermediates as mediators of programmed cell death in plants and animals. Biochem Pharmacol 1999; 57: 231-45.
22. Poyton RO, Ball KA, Castello PR. Mitochondrial generation of free radicals and hypoxic signaling. Trends Endocrinol Metab 2009; 20: 332-40.
23. Kundu N, Zhang S, Fulton AM. Sublethal oxidative stress inhibits tumor cell adhesion and enhances experimental metastasis of murine mammary carcinoma. Clin Exp Metastasis 1995; 13: 16-22.
24. Roebuck KA. Oxidant stress regulation of IL-8 and ICAM-1 gene expression: differential activation and binding of the transcription factors AP-1 and NF-kappaB (Review). Int J Mol Med 1999; 4: 223-30.
25. Barnett P, Arnold RS, Mezencev R, et al. Snail-mediated regulation of reactive oxygen species in ARCaP human prostate cancer cells. Biochem Biophys Res Commun 2011; 404: 34-9.
26. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999; 13: 781-92.
27. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000; 18: 1135-49.
28. Mori K, Shibanuma M, Nose K. Invasive potential induced under long-term oxidative stress in mammary epithelial cells. Cancer Res 2004; 64: 7464-72.
29. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophagederived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 1996; 98: 2572-9.
30. Nelson KK, Melendez JA. Mitochondrial redox control of matrix metalloproteinases. Free Radic Biol Med 2004; 37: 768-84.
31. Yoon SO, Park SJ, Yoon SY, Yun CH, Chung AS. Sustained production of H(2)O(2) activates pro-matrix metalloproteinase-2 through receptor tyrosine kinases/phosphatidylinositol 3-kinase/NF-kappa B pathway. J Biol Chem 2002; 277: 30271-82.
32. Storz P. Reactive oxygen species in tumor progression. Front Biosci 2005; 10: 1881-96.
33. Kollmar O, Rupertus K, Scheuer C, et al. Stromal cell-derived factor-1 promotes cell migration and tumor growth of colorectal metastasis. Neoplasia 2007; 9: 862-70.
34. Yuecheng Y, Xiaoyan X. Stromal-cell derived factor-1 regulates epithelial ovarian cancer cell invasion by activating matrix metalloproteinase-9 and matrix metalloproteinase-2. Eur J Cancer Prev 2007; 16: 430-5.
35. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res 2006; 4: 221-33.
36. Mongaret C, Alexandre J, Thomas-Schoemann A, et al. Tumor invasion induced by oxidative stress is dependent on membrane ADAM 9 protein and its secreted form. Int J Cancer 2011; 129: 791-8.
37. van Wetering S, van Buul JD, Quik S, et al. Reactive oxygen species mediate Rac-induced loss of cell-cell adhesion in primary human endothelial cells. J Cell Sci 2002; 115: 1837-46.
38. Al-Mulla F, Bitar MS, Al-Maghrebi M, et al. Raf kinase inhibitor protein RKIP enhances signaling by glycogen synthase kinase-3beta. Cancer Res 2011; 71: 1334-43.
39. Diers AR, Dranka BP, Ricart KC, et al. Modulation of mammary cancer cell migration by 15-deoxy-delta(12,14)- prostaglandin J(2): implications for anti-metastatic therapy. Biochem J 2010; 430: 69-78.
40. Stamatakis K, Sanchez-Gomez FJ, Perez-Sala D. Identification of novel protein targets for modification by 15- deoxy-Delta12,14-prostaglandin J2 in mesangial cells reveals multiple interactions with the cytoskeleton. J Am Soc Nephrol 2006; 17: 89-98.
41. Behrend L, Mohr A, Dick T, Zwacka RM. Manganese superoxide dismutase induces p53-dependent senescence in colorectal cancer cells. Mol Cell Biol 2005; 25: 7758-69.
42. Shao C, Folkard M, Held KD, Prise KM. Estrogen enhanced cell-cell signalling in breast cancer cells exposed to targeted irradiation. BMC Cancer 2008; 8: 184.
43. Malins DC, Haimanot R. Major alterations in the nucleotide structure of DNA in cancer of the female breast. Cancer Res 1991; 51: 5430-2.
44. Malins DC, Holmes EH, Polissar NL, Gunselman SJ. The etiology of breast cancer. Characteristic alteration in hydroxyl radical-induced DNA base lesions during oncogenesis with potential for evaluating incidence risk. Cancer 1993; 71: 3036-43.
45. Musarrat J, Arezina-Wilson J, Wani AA. Prognostic and aetiological relevance of 8-hydroxyguanosine in human breast carcinogenesis. Eur J Cancer 1996; 32A: 1209-14.
46. Lee AH, Happerfield LC, Bobrow LG, Millis RR. Angiogenesis and inflammation in invasive carcinoma of the breast. J Clin Pathol 1997; 50: 669-73.
47. Felty Q, Singh KP, Roy D. Estrogen-induced G1/S transition of G0-arrested estrogen-dependent breast cancer cells is regulated by mitochondrial oxidant signaling. Oncogene 2005; 24: 4883-93.
48. Okoh V, Deoraj A, Roy D. Estrogen-induced reactive oxygen species-mediated signalings contribute to breast cancer. Biochim Biophys Acta 2011; 1815: 115-33.
49. Huang Y, Fernandez SV, Goodwin S, et al. Epithelial to mesenchymal transition in human breast epithelial cells transformed by 17beta-estradiol. Cancer Res 2007; 67: 11147-57.
50. Ye Y, Xiao Y, Wang W, et al. ERalpha signaling through slug regulates E-cadherin and EMT. Oncogene 2010; 29: 1451-62.
51. Wang X, Belguise K, Kersual N, et al. Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat Cell Biol 2007; 9: 470-8.
52. Ho CC, Ling YC, Chang LW, et al. 17-Beta estradiol and hydroxyestradiols interact via the NF-kappa B pathway to elevate cyclooxygenase 2 expression and prostaglandin E2 secretion in human bronchial epithelial cells. Toxicol Sci 2008; 104: 294-302.
53. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009; 9: 537-49.
54. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001; 81: 807-69.
55. Benhar M, Dalyot I, Engelberg D, Levitzki A. Enhanced ROS production in oncogenically transformed cells potentiates c- Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. Mol Cell Biol 2001; 21: 6913-26.
56. Matsuzawa A, Ichijo H. Redox control of cell fate by MAP kinase: physiological roles of ASK1-MAP kinase pathway in stress signaling. Biochim Biophys Acta 2008; 1780: 1325-36.
57. Nadeau PJ, Charette SJ, Toledano MB, Landry J. Disulfide Bond-mediated multimerization of Ask1 and its reduction by thioredoxin-1 regulate H(2)O(2)-induced c-Jun NH(2)- terminal kinase activation and apoptosis. Mol Biol Cell 2007; 18: 3903-13.
58. Zhao H, Yan M, Wang H, et al. Impaired c-Jun amino terminal kinase activity and T cell differentiation in death receptor 6-deficient mice. J Exp Med 2001; 194: 1441-8.
59. Torres M. Mitogen-activated protein kinase pathways in redox signaling. Front Biosci 2003; 8: d369-91.
60. Benhar M, Engelberg D, Levitzki A. ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep 2002; 3: 420-5.
61. Yoshida BA, Dubauskas Z, Chekmareva MA, et al. Mitogenactivated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res 1999; 59: 5483-7.
62. Magi-Galluzzi C, Xu X, Hlatky L, et al. Heterogeneity of androgen receptor content in advanced prostate cancer. Mod Pathol 1997; 10: 839-45.
63. Laderoute KR, Mendonca HL, Calaoagan JM, et al. Mitogenactivated protein kinase phosphatase-1 (MKP-1) expression is induced by low oxygen conditions found in solid tumor microenvironments. A candidate MKP for the inactivation of hypoxia-inducible stress-activated protein kinase/c-Jun Nterminal protein kinase activity. J Biol Chem 1999; 274: 12890-7.
64. Wu WS, Wu JR, Hu CT. Signal cross talks for sustained MAPK activation and cell migration: the potential role of reactive oxygen species. Cancer Metastasis Rev 2008; 27: 303-14.
65. Dittmer J. The biology of the Ets1 proto-oncogene. Mol Cancer 2003; 2: 29.
66. Rothhammer T, Hahne JC, Florin A, et al. The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma. Cell Mol Life Sci 2004; 61: 118-28.
67. Park YH, Jung HH, Ahn JS, Im YH. Ets-1 upregulates HER2- induced MMP-1 expression in breast cancer cells. Biochem Biophys Res Commun 2008; 377: 389-94.
68. Shimizu S, Hiroi T, Ishii M, et al. Hydrogen peroxide stimulates tetrahydrobiopterin synthesis through activation of the Jak2 tyrosine kinase pathway in vascular endothelial cells. Int J Biochem Cell Biol 2008; 40: 755-65.
69. Duvoix A, Schnekenburger M, Delhalle S, et al. Expression of glutathione S-transferase P1-1 in leukemic cells is regulated by inducible AP-1 binding. Cancer Lett 2004; 216: 207-19.
70. Salnikow K, Aprelikova O, Ivanov S, et al. Regulation of hypoxia-inducible genes by ETS1 transcription factor. Carcinogenesis 2008; 29: 1493-9.
71. Wilson LA, Gemin A, Espiritu R, Singh G. ets-1 is transcriptionally up-regulated by H2O2 via an antioxidant response element. FASEB J 2005; 19: 2085-7.
72. Sanij E, Hatzistavrou T, Hertzog P, Kola I, Wolvetang EJ. Ets-2 is induced by oxidative stress and sensitizes cells to H(2)O(2)-induced apoptosis: implications for Down's syndrome. Biochem Biophys Res Commun 2001; 287: 1003-8.
73. Monge M, Colas E, Doll A, et al. ERM/ETV5 up-regulation plays a role during myometrial infiltration through matrix metalloproteinase-2 activation in endometrial cancer. Cancer Res 2007; 67: 6753-9.
74. Monge M, Colas E, Doll A, et al. Proteomic approach to ETV5 during endometrial carcinoma invasion reveals a link to oxidative stress. Carcinogenesis 2009; 30: 1288-97.
75. Monge M, Doll A, Colas E, et al. Subtractive proteomic approach to the endometrial carcinoma invasion front. J Proteome Res 2009; 8: 4676-84.
76. Kundu JK, Surh YJ. Nrf2-Keap1 signaling as a potential target for chemoprevention of inflammation-associated carcinogenesis. Pharm Res 2011; 27: 999-1013.
77. Hayes JD, McMahon M. Molecular basis for the contribution of the antioxidant responsive element to cancer chemoprevention. Cancer Lett 2001; 174: 103-13.
78. Kim SK, Yang JW, Kim MR, et al. Increased expression of Nrf2/ARE-dependent anti-oxidant proteins in tamoxifenresistant breast cancer cells. Free Radic Biol Med 2008; 45: 537-46.
79. Bae I, Fan S, Meng Q, et al. BRCA1 induces antioxidant gene expression and resistance to oxidative stress. Cancer Res 2004; 64: 7893-909.
80. Satoh H, Moriguchi T, Taguchi K, et al. Nrf2-deficiency creates a responsive microenvironment for metastasis to the lung. Carcinogenesis 2010; 31: 1833-43.
81. Shibata T, Saito S, Kokubu A, et al. Global downstream pathway analysis reveals a dependence of oncogenic NFE2- related factor 2 mutation on the mTOR growth signaling pathway. Cancer Res 2010; 70: 9095-105.
82. Wang XJ, Sun Z, Villeneuve NF, et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 2008; 29: 1235-43.
83. Taguchi K, Motohashi H, Yamamoto M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 2011; 16: 123-40.
84. Sethi G, Sung B, Aggarwal BB. Nuclear factor-kappaB activation: from bench to bedside. Exp Biol Med (Maywood) 2008; 233: 21-31.
85. Park SA, Na HK, Kim EH, Cha YN, Surh YJ. 4- hydroxyestradiol induces anchorage-independent growth of human mammary epithelial cells via activation of IkappaB kinase: potential role of reactive oxygen species. Cancer Res 2009; 69: 2416-24.
86. Hacker H, Karin M. Regulation and function of IKK and IKKrelated kinases. Sci STKE 2006; re13.
87. Kabe Y, Ando K, Hirao S, Yoshida M, Handa H. Redox regulation of NF-kappaB activation: distinct redox regulation between the cytoplasm and the nucleus. Antioxid Redox Signal 2005; 7: 395-403.
88. Hirota K, Matsui M, Iwata S, et al. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci USA 1997; 94: 3633-8.
89. Hirota K, Murata M, Sachi Y, et al. Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NFkappaB. J Biol Chem 1999; 274: 27891-7.
90. Li Q, Engelhardt JF. Interleukin-1beta induction of NFkappaB is partially regulated by H2O2-mediated activation of NFkappaB-inducing kinase. J Biol Chem 2006; 281: 1495-505.
91. Matthews JR, Watson E, Buckley S, Hay RT. Interaction of the C-terminal region of p105 with the nuclear localisation signal of p50 is required for inhibition of NF-kappa B DNA binding activity. Nucleic Acids Res 1993; 21: 4516-23.
92. Takada Y, Aggarwal BB. Genetic deletion of the tumor necrosis factor receptor p60 or p80 sensitizes macrophages to lipopolysaccharide-induced nuclear factor-kappa B, mitogen-activated protein kinases, and apoptosis. J Biol Chem 2003; 278: 23390-7.
93. Qu Y, Wang J, Ray PS, et al. Thioredoxin-like 2 regulates human cancer cell growth and metastasis via redox homeostasis and NF-kappaB signaling. J Clin Invest 2011; 121: 212-25.
94. Cheng GC, Schulze PC, Lee RT, et al. Oxidative stress and thioredoxin-interacting protein promote intravasation of melanoma cells. Exp Cell Res 2004; 300: 297-307.
95. Palozza P, Serini S, Torsello A, et al. Beta-carotene regulates NF-kappaB DNA-binding activity by a redox mechanism in human leukemia and colon adenocarcinoma cells. J Nutr 2003; 133: 381-8.
96. Morgan MJ, Liu ZG. Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res 2011; 21: 103-15.
97. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxiainducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92: 5510-4.
98. Lisztwan J, Imbert G, Wirbelauer C, Gstaiger M, Krek W. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev 1999; 13: 1822-33.
99. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxiainducible factor 1alpha. Genes Dev 2000; 14: 34-44.
100. Talks KL, Turley H, Gatter KC, et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumorassociated macrophages. Am J Pathol 2000; 157: 411-21.
101. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999; 59: 5830-5.
102. Winter SC, Shah KA, Han C, et al. The relation between hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer. Cancer 2006; 107: 757-66.
103. Bos R, van der Groep P, Greijer AE, et al. Levels of hypoxiainducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003; 97: 1573-81.
104. Chaudary N, Hill RP. Hypoxia and metastasis in breast cancer. Breast Dis 2006; 26: 55-64.
105. Ruan K, Song G, Ouyang G. Role of hypoxia in the hallmarks of human cancer. J Cell Biochem 2009; 107: 1053-62.
106. Zhou Q, Liu LZ, Fu B, et al. Reactive oxygen species regulate insulin-induced VEGF and HIF-1alpha expression through the activation of p70S6K1 in human prostate cancer cells. Carcinogenesis 2007; 28: 28-37.
107. Gao N, Shen L, Zhang Z, et al. Arsenite induces HIF-1alpha and VEGF through PI3K, Akt and reactive oxygen species in DU145 human prostate carcinoma cells. Mol Cell Biochem 2004; 255: 33-45.
108. Erler JT, Bennewith KL, Nicolau M, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006; 440: 1222-6.
109. Pennacchietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003; 3: 347-61.
110. Law AY, Wong CK. Stanniocalcin-2 promotes epithelialmesenchymal transition and invasiveness in hypoxic human ovarian cancer cells. Exp Cell Res 2010; 316: 3425-34.
111. Jiang YG, Luo Y, He DL, et al. Role of Wnt/beta-catenin signaling pathway in epithelial-mesenchymal transition of human prostate cancer induced by hypoxia-inducible factor- 1alpha. Int J Urol 2007; 14: 1034-9.
112. Kagan HM, Li W. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem 2003; 88: 660-72.
113. Cairns RA, Khokha R, Hill RP. Molecular mechanisms of tumor invasion and metastasis: an integrated view. Curr Mol Med 2003; 3: 659-71.
114. Chang HY, Nuyten DS, Sneddon JB, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005; 102: 3738-43.
115. Payne SL, Fogelgren B, Hess AR, et al. Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism. Cancer Res 2005; 65: 11429-36.
116. Levental KR, Yu H, Kass L, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009; 139: 891-906.
117. Solinas G, Germano G, Mantovani A, Allavena P. Tumorassociated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 2009; 86: 1065-73.
118. Tokino T, Nakamura Y. The role of p53-target genes in human cancer. Crit Rev Oncol Hematol 2000; 33: 1-6.
119. Prives C, Hall PA. The p53 pathway. J Pathol 1999; 187: 112-26.
120. Sablina AA, Budanov AV, Ilyinskaya GV, et al. The antioxidant function of the p53 tumor suppressor. Nat Med 2005; 11: 1306-13.
121. Lebedeva MA, Eaton JS, Shadel GS. Loss of p53 causes mitochondrial DNA depletion and altered mitochondrial reactive oxygen species homeostasis. Biochim Biophys Acta 2009; 1787: 328-34.
122. Samper E, Morgado L, Estrada JC, et al. Increase in mitochondrial biogenesis, oxidative stress, and glycolysis in murine lymphomas. Free Radic Biol Med 2009; 46: 387-96.
123. Qian J, Hirasawa K, Bostwick DG, et al. Loss of p53 and cmyc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression. Mod Pathol 2002; 15: 35-44.
124. Olinski R, Gackowski D, Rozalski R, Foksinski M, Bialkowski K. Oxidative DNA damage in cancer patients: a cause or a consequence of the disease development? Mutat Res 2003; 531: 177-90.
125. Soini Y, Haapasaari KM, Vaarala MH, et al. 8- hydroxydeguanosine and nitrotyrosine are prognostic factors in urinary bladder carcinoma. Int J Clin Exp Pathol 2011; 4: 267-75.
126. Dizdaroglu M, Kirkali G, Jaruga P. Formamidopyrimidines in DNA: mechanisms of formation, repair, and biological effects. Free Radic Biol Med 2008; 45: 1610-21.
127. Milne GL, Yin H, Morrow JD. Human biochemistry of the isoprostane pathway. J Biol Chem 2008; 283: 15533-7.
128. Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem 2004; 266: 37-56.
129. Milne GL, Musiek ES, Morrow JD. F2-isoprostanes as markers of oxidative stress in vivo: an overview. Biomarkers 2005; 10 Suppl 1: S10-23.
130. Delker D, Hatch G, Allen J, et al. Molecular biomarkers of oxidative stress associated with bromate carcinogenicity. Toxicology 2006; 221: 158-65.
131. Kimoto Y, Sugiyama A, Nishinohara M, et al. Expressions of protein oxidation markers, dityrosine and advanced oxidation protein products in Cisplatin-induced nephrotoxicity in rats. J Vet Med Sci 2011; 73: 403-7.
132. Katahira T, Takayama T, Miyanishi K, et al. Plasma glutathione S-Transferase P1-1 as a prognostic factor in patients with advanced non-Hodgkin's lymphoma (stages III and IV). Clin Cancer Res 2004; 10: 7934-40.
133. Kim HM, Haraguchi N, Ishii H, et al. Increased CD13 Expression Reduces Reactive Oxygen Species, Promoting Survival of Liver Cancer Stem Cells via an Epithelial- Mesenchymal Transition-like Phenomenon. Ann Surg Oncol 2011 (Epub ahead of schedule).
134. Xu M, Bower KA, Wang S, et al. Cyanidin-3-glucoside inhibits ethanol-induced invasion of breast cancer cells overexpressing ErbB2. Mol Cancer 2010; 9: 285.
135. Anasagasti MJ, Alvarez A, Martin JJ, Mendoza L, Vidal- Vanaclocha F. Sinusoidal endothelium release of hydrogen peroxide enhances very late antigen-4-mediated melanoma cell adherence and tumor cytotoxicity during interleukin-1 promotion of hepatic melanoma metastasis in mice. Hepatology 1997; 25: 840-6.
136. Behrend L, Henderson G, Zwacka RM. Reactive oxygen species in oncogenic transformation. Biochem Soc Trans 2003; 31: 1441-4.
137. Carew JS, Zhou Y, Albitar M, et al. Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implications. Leukemia 2003; 17: 1437-47.
138. Siddiqui IA, Adhami VM, Saleem M, Mukhtar H. Beneficial effects of tea and its polyphenols against prostate cancer. Mol Nutr Food Res 2006; 50: 130-43.
139. Seifried HE. Oxidative stress and antioxidants: a link to disease and prevention? J Nutr Biochem 2007; 18: 168-71.
140. Conklin KA. Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects. Nutr Cancer 2000; 37: 1-18.
141. Kelkel M, Jacob C, Dicato M, Diederich M. Potential of the dietary antioxidants resveratrol and curcumin in prevention and treatment of hematologic malignancies. Molecules 2010; 15: 7035-74.
142. Kraft TE, Parisotto D, Schempp C, Efferth T. Fighting cancer with red wine? Molecular mechanisms of resveratrol. Crit Rev Food Sci Nutr 2009; 49: 782-99.
143. Nelson SK, Bose SK, Grunwald GK, Myhill P, McCord JM. The induction of human superoxide dismutase and catalase in vivo: a fundamentally new approach to antioxidant therapy. Free Radic Biol Med 2006; 40: 341-7.
144. Ogino T, Inoue M, Ando Y, et al. Chemical modification of superoxide dismutase. Extension of plasma half life of the enzyme through its reversible binding to the circulating albumin. Int J Pept Protein Res 1988; 32: 153-9.
145. Rabbani ZN, Spasojevic I, Zhang X, et al. Antiangiogenic action of redox-modulating Mn(III) meso-tetrakis(Nethylpyridinium- 2-yl)porphyrin, MnTE-2-PyP(5+), via suppression of oxidative stress in a mouse model of breast tumor. Free Radic Biol Med 2009; 47: 992-1004.
146. Kogure T, Ueno Y, Kimura O, et al. A novel third generation bisphosphonate, minodronate (YM529), prevented proliferation and migration of hepatocellular carcinoma cells through inhibition of mevalonate pathway. Hepatol Res 2009; 39: 479-89.
147. Yamagishi S, Abe R, Inagaki Y, et al. Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling. Am J Pathol 2004; 165: 1865-74.
148. Hileman EO, Liu J, Albitar M, Keating MJ, Huang P. Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol 2004; 53: 209-19.
149. Renschler MF. The emerging role of reactive oxygen species in cancer therapy. Eur J Cancer 2004; 40: 1934-40.
150. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008; 111: 2505-15.
151. Chou WC, Jie C, Kenedy AA, et al. Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc Natl Acad Sci USA 2004; 101: 4578-83.
152. Pelicano H, Feng L, Zhou Y, et al. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem 2003; 278: 37832-9.
153. Park MJ, Lee JY, Kwak HJ, et al. Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species. J Cell Biochem 2005; 95: 955-69.
154. Tsang WP, Chau SP, Kong SK, Fung KP, Kwok TT. Reactive oxygen species mediate doxorubicin induced p53- independent apoptosis. Life Sci 2003; 73: 2047-58.
155. Gouaze V, Mirault ME, Carpentier S, et al. Glutathione peroxidase-1 overexpression prevents ceramide production and partially inhibits apoptosis in doxorubicin-treated human breast carcinoma cells. Mol Pharmacol 2001; 60: 488-96.
156. Miyajima A, Nakashima J, Yoshioka K, et al. Role of reactive oxygen species in cis-dichlorodiammineplatinum-induced cytotoxicity on bladder cancer cells. Br J Cancer 1997; 76: 206-10.
157. Hug H, Strand S, Grambihler A, et al. Reactive oxygen intermediates are involved in the induction of CD95 ligand mRNA expression by cytostatic drugs in hepatoma cells. J Biol Chem 1997; 272: 28191-3.
158. Ling YH, Liebes L, Zou Y, Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 2003; 278: 33714-23.
159. Thomas-Schoemann A, Lemare F, Mongaret C, et al. Bystander effect of vinorelbine alters antitumor immune response. Int J Cancer 2010; 129: 1511-8.
160. Engel RH, Evens AM. Oxidative stress and apoptosis: a new treatment paradigm in cancer. Front Biosci 2006; 11: 300-12.
161. Juarez JC, Betancourt O, Jr., Pirie-Shepherd SR, et al. Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res 2006; 12: 4974-82.
162. Juarez JC, Manuia M, Burnett ME, et al. Superoxide dismutase 1 (SOD1) is essential for H2O2-mediated oxidation and inactivation of phosphatases in growth factor signaling. Proc Natl Acad Sci USA 2008; 105: 7147-52.
163. Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 2000; 407: 390-5.
164. Imai S, Yoshida Y, Okamura T, et al. The specific effect of 2- methoxyestradiol on lymphatic vascular endothelial cells. Pharmazie 2009; 64: 214-6.
165. Biaglow JE, Miller RA. The thioredoxin reductase/thioredoxin system: novel redox targets for cancer therapy. Cancer Biol Ther 2005; 4: 6-13.
166. Yoo MH, Xu XM, Carlson BA, Gladyshev VN, Hatfield DL. Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J Biol Chem 2006; 281: 13005-8.
167. Powis G, Wipf P, Lynch SM, Birmingham A, Kirkpatrick DL. Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase. Mol Cancer Ther 2006; 5: 630-6.
168. Welsh SJ, Williams RR, Birmingham A, et al. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther 2003; 2: 235-43.
169. Yoshida A, Takemura H, Inoue H, Miyashita T, Ueda T. Inhibition of glutathione synthesis overcomes Bcl-2-mediated topoisomerase inhibitor resistance and induces nonapoptotic cell death via mitochondrial-independent pathway. Cancer Res 2006; 66: 5772-80.
170. Chatterjee S, Mookerjee A, Basu JM, et al. A novel copper chelate modulates tumor associated macrophages to promote anti-tumor response of T cells. PLoS One 2009; 4: e7048.
171. Gianni D, Taulet N, Zhang H, et al. A novel and specific NADPH oxidase-1 (Nox1) small-molecule inhibitor blocks the formation of functional invadopodia in human colon cancer cells. ACS Chem Biol 2010; 5: 981-93.
172. Tobar N, Villar V, Santibanez JF. ROS-NFkappaB mediates TGF-beta1-induced expression of urokinase-type plasminogen activator, matrix metalloproteinase-9 and cell invasion. Mol Cell Biochem 2010; 340: 195-202.
173. Gottlieb E, Tomlinson IP. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev Cancer 2005; 5: 857-66.
174. Mroz P, Tegos GP, Gali H, et al. Photodynamic therapy with fullerenes. Photochem Photobiol Sci 2007; 6: 1139-49.
175. Jalili A, Makowski M, Switaj T, et al. Effective photoimmunotherapy of murine colon carcinoma induced by the combination of photodynamic therapy and dendritic cells. Clin Cancer Res 2004; 10: 4498-508.
176. Dougherty TJ. An update on photodynamic therapy applications. J Clin Laser Med Surg 2002; 20: 3-7.
177. Yi J, Yang J, He R, et al. Emodin enhances arsenic trioxideinduced apoptosis via generation of reactive oxygen species and inhibition of survival signaling. Cancer Res 2004; 64: 108-16.
178. Young O, Crotty T, O'Connell R, O'Sullivan J, Curran AJ. Levels of oxidative damage and lipid peroxidation in thyroid neoplasia. Head Neck 2010; 32: 750-6.
179. Jo M, Nishikawa T, Nakajima T, et al. Oxidative stress is closely associated with tumor angiogenesis of hepatocellular carcinoma. J Gastroenterol 2011; 46: 809-21.
180. Malins DC, Haimanot R. 4,6-Diamino-5- formamidopyrimidine, 8-hydroxyguanine and 8- hydroxyadenine in DNA from neoplastic liver of English sole exposed to carcinogens. Biochem Biophys Res Commun 1990; 173: 614-9.
181. Mordukhovich I, Rossner P, Jr., Terry MB, et al. Associations between polycyclic aromatic hydrocarbon-related exposures and p53 mutations in breast tumors. Environ Health Perspect 2011; 118: 511-8.
182. Castano-Vinyals G, Talaska G, Rothman N, et al. Bulky DNA adduct formation and risk of bladder cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 2155-9.
183. Il'yasova D, Kennedy K, Spasojevic I, et al. Individual responses to chemotherapy-induced oxidative stress. Breast Cancer Res Treat 2011; 125: 583-9.
184. Lim KH, Lee CY, Earnest A, Seet RC, Halliwell B. Does radiotherapy increase oxidative stress? A study with nasopharyngeal cancer patients revealing anomalies in isoprostanes measurements. Free Radic Res 2010; 44: 1064-71.
185. Chang D, Wang F, Zhao YS, Pan HZ. Evaluation of oxidative stress in colorectal cancer patients. Biomed Environ Sci 2008; 21: 286-9.
186. Peluso M, Munnia A, Risso GG, et al. Breast fine-needle aspiration malondialdehyde deoxyguanosine adduct in breast cancer. Free Radic Res 2011; 45: 477-82.
187. Chole RH, Patil RN, Basak A, Palandurkar K, Bhowate R. Estimation of serum malondialdehyde in oral cancer and precancer and its association with healthy individuals, gender, alcohol, and tobacco abuse. J Cancer Res Ther 2010; 6: 487-91.
188. Quiros I, Sainz RM, Hevia D, et al. Upregulation of manganese superoxide dismutase (SOD2) is a common pathway for neuroendocrine differentiation in prostate cancer cells. Int J Cancer 2009; 125: 1497-504.
189. Pawlowicz Z, Zachara BA, Trafikowska U, et al. Blood selenium concentrations and glutathione peroxidase activities in patients with breast cancer and with advanced gastrointestinal cancer. J Trace Elem Electrolytes Health Dis 1991; 5: 275-7.
190. Yu YP, Yu G, Tseng G, et al. Glutathione peroxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer growth and metastasis. Cancer Res 2007; 67: 8043-50.
191. Fernandes AP, Capitanio A, Selenius M, et al. Expression profiles of thioredoxin family proteins in human lung cancer tissue: correlation with proliferation and differentiation. Histopathology 2009; 55: 313-20.
192. Deng ZH, Cao HQ, Hu YB, Wen JF, Zhou JH. TRX is upregulated by fibroblast growth factor-2 in lung carcinoma. APMIS 2011: 119: 57-65.
193. Singh SS, Li Y, Ford OH, et al. Thioredoxin reductase 1 expression and castration-recurrent growth of prostate cancer. Transl Oncol 2008; 1: 153-7.